Synthesis and evaluation of a 99mTechnetium labeled chitin-binding protein as potential specific radioligand for the detection of fungal infections in mice. by Siaens, R, Eijsink, V, Vaaje-Kolstad, G, Vandenbulcke, K, Cornelissen, B, Cuvelier, C, Dierckx, R, Slegers, G

“…AIM: Radiopharmaceuticals can be used to exploit differences between microorganisms in order to distinguish fungal from bacterial infection. …”

Preparation, optimisation, and in vitro evaluation of [¹⁸F] AlF-NOTA-Pamidronic acid for bone imaging PET by Hishar Hassan, Muhamad Faiz Othman, Hairil Rashmizal Abdul Razak, Zainul Amiruddin Zakaria, Fathinul Fikri Ahmad Saad, Mohd Azuraidi Osman, Loh, Hui Yi, Zarif Ashhar, Jaleezah Idris, Mohd Hamdi Noor Abdul Hamid, Zaitulhusna M. Safee

“…Radiolabeling of [¹⁸F] AlF-NOTA-pamidronic acid was optimised, and it was ensured that all quality control analysis requirements for the radiopharmaceuticals were met prior to the in vitro cell uptake studies. …”
Get full text
Get full text

Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy by O'Neill, E, Kersemans, V, Allen, P, Terry, S, Baguna Torres, J, Mosley, M, Smart, S, Lee, B, Falzone, N, Vallis, K, Konijnenberg, M, De Jong, M, Nonnekens, J, Cornelissen, B

“…This work was a proof-of-principle study of this in vivo noninvasive biodosimeter with &beta;-emitting therapeutic radiopharmaceuticals.&nbsp;<strong>Methods:</strong>&nbsp;Six cell lines were exposed to external-beam radiotherapy (EBRT) or&nbsp;¹⁷⁷Lu-DOTATATE, after which the number of &gamma;H2AX foci and the clonogenic survival were measured. …”

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. by Reilly, R, Scollard, D, Wang, J, Mondal, H, Chen, P, Henderson, L, Bowen, B, Vallis, K

“…Establishment of the GMP processes for (111)In-DTPA-hEGF Injection provides a useful example of manufacturing biotechnology-based investigational radiopharmaceuticals in an academic environment for early phase I clinical trials.…”

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiati... by Cornelissen, B, Darbar, S, Hernandez, R, Kersemans, V, Tullis, I, Barber, P, Smart, S, Vojnovic, B, Reilly, R, Vallis, K

“…The intracellular distribution of Auger electron-emitting radiopharmaceuticals is a determinant of cytotoxicity. However, the mechanisms by which these agents are routed through the cell are ill understood. …”

Comparison of uptake 99mTcO4; 99mTc-DTPA and 99mTc-MDP by breast cancer cell line. by Rafzi, Siti Noraisyah

“…The aim of this study is to determine the percentage uptake of different tracer by the breast cancer cell line (MCF-7), hence finding the optimum condition for the cells to absorb the radiopharmaceuticals. In addition, this study is to investigate the number of cell viable for different radioactivity with different type of tracers used. …”
Get full text

Comparison of uptake 99mTcO4; 99mTc-dtpa and "mTc-mdp by breast cancer cell line. by Rafzi, Siti Noraisyah

“…The aim of this study is to determine the percentage uptake of different tracer by the breast cancer cell line (MCF-7), hence finding the optimum condition for the cells to absorb the radiopharmaceuticals. In addition, this study is to investigate the number of cell viable for different radioactivity with different type of tracers used. …”
Get full text

Quantitative comparison between low energy high resolution (LEHR) and medium energy general purpose (MEGP) collimator on nema spect imaging by Paramesivam, Divya

“…Nuclear medicine leverages radioactive materials, known as radiopharmaceuticals or radiotracers, for diagnosing and treating diseases. …”
Get full text

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. by Kaltsas, G, Mukherjee, J, Isidori, A, Kola, B, Plowman, P, Monson, J, Grossman, AB, Besser, G

“…It may therefore be a valuable additional therapeutic option, particularly for well-differentiated carcinoid and islet-cell tumours, but mainly reserved for when there is no response or progression of the disease after currently available first-line treatment with somatostatin analogues or radiopharmaceuticals.…”